Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.81
Nov 11 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Aftermarket Close
1.81
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
19.67M
Enterprise Value
11.47M
Income
-14.25M
Sales
57.57M
Book/sh
3.29
Cash/sh
2.42
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
76
IPO
Sep 24, 2008
P/E
-
Forward P/E
6.70
PEG
-
P/S
0.34
P/B
0.55
P/C
0.75
P/FCF
6.05
EV/EBITDA
-
EV/Sales
0.20
Quick Ratio
1.00
Current Ratio
1.13
Debt/Eq
0.51
LT Debt/Eq
0.28
Option/Short
No / Yes
EPS (ttm)
-1.67
EPS next Y
0.27
EPS next Q
-0.26
EPS this Y
46.26%
EPS next Y
143.32%
EPS next 5Y
-
EPS past 3/5Y
39.03% 55.93%
Sales past 3/5Y
-18.77% -2.59%
EPS Y/Y TTM
27.11%
Sales Y/Y TTM
-13.27%
EPS Q/Q
99.97%
Sales Q/Q
6.42%
Insider Own
8.26%
Insider Trans
0.00%
Inst Own
35.61%
Inst Trans
-4.61%
ROA
-12.41%
ROE
-52.55%
ROIC
-31.51%
Gross Margin
59.62%
Oper. Margin
-12.57%
Profit Margin
-24.76%
SMA20
-5.75%
SMA50
-10.96%
SMA200
-20.75%
Trades
Shs Outstand
10.73M
Shs Float
9.97M
52W High
3.07 -40.95%
52W Low
1.75 3.43%
Volatility
8.48% 5.49%
ATR (14)
0.10
RSI (14)
35.74
Beta
0.22
Rel Volume
0.33
Avg Volume
34.64K
Volume
11,336
Perf Week
-5.73%
Perf Month
-9.05%
Perf Quarter
-21.30%
Perf Half Y
-19.56%
Perf YTD
-30.38%
Perf Year
-13.81%
Perf 3Y
-37.80%
Perf 5Y
-96.26%
Perf 10Y
-100.00%
Prev Close
1.81
Price
1.81
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$9.67
Implied Upside
+434.3%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 01, 2025Initiated
LLake Street
Buy$8+342.0%
Jun 30, 2025Initiated
AAscendiant Capital Markets
Buy$12+563.0%
Mar 30, 2021Initiated
CCantor Fitzgerald
Overweight$11+507.7%
May 29, 2020Initiated
HH.C. Wainwright
Buy$3+65.7%
Aytu BioPharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. Its products include EXXUA, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, and Metadate CD. The company was founded on August 9, 2002 and is headquartered in Denver, CO.
CEO & DirectorMr. Joshua R. Disbrow
CFOMr. Ryan J. Selhorn C.P.A.
Chief Business OfficerMr. Jarrett T. Disbrow Ph.D.
Chief Commercial OfficerMr. Greg Pyszczymuka
Vice President of OperationsMs. Margaret Cabano